Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

118 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Prevalence of mutations and determinants of genotypic resistance to etravirine (TMC125) in a large Italian resistance database (ARCA).
Di Vincenzo P, Rusconi S, Adorni F, Vitiello P, Maggiolo F, Francisci D, Di Biagio A, Monno L, Antinori A, Boeri E, Punzi G, Perno CF, Callegaro A, Bruzzone B, Zazzi M; Antiretroviral Resistance Cohort Analysis (ARCA) Collaborative Group. Di Vincenzo P, et al. Among authors: vitiello p. HIV Med. 2010 Sep;11(8):530-4. doi: 10.1111/j.1468-1293.2009.00819.x. Epub 2010 Mar 8. HIV Med. 2010. PMID: 20236364 Free article.
Factors associated with virological success with raltegravir-containing regimens and prevalence of raltegravir-resistance-associated mutations at failure in the ARCA database.
Rusconi S, Vitiello P, Adorni F, Bruzzone B, De Luca A, Micheli V, Meraviglia P, Maserati R, Di Pietro M, Colao G, Penco G, Di Biagio A, Punzi G, Monno L, Zazzi M; Antiretroviral Resistance Cohort Analysis Collaborative Group. Rusconi S, et al. Among authors: vitiello p. Clin Microbiol Infect. 2013 Oct;19(10):936-42. doi: 10.1111/1469-0691.12100. Epub 2013 Jan 4. Clin Microbiol Infect. 2013. PMID: 23289841 Free article.
Comparative evaluation of seven resistance interpretation algorithms and their derived genotypic inhibitory quotients for the prediction of 48 week virological response to darunavir-based salvage regimens.
Gonzalez de Requena D, Bonora S, Viganò O, Calcagno A, Cometto C, D'Avolio A, Baietto L, Ghisetti V, Magnani S, Ferramosca S, Vitiello P, Galli M, Rusconi S, Di Perri G. Gonzalez de Requena D, et al. Among authors: vitiello p. J Antimicrob Chemother. 2011 Jan;66(1):192-200. doi: 10.1093/jac/dkq384. Epub 2010 Oct 29. J Antimicrob Chemother. 2011. PMID: 21037251 Free article.
Maraviroc as intensification strategy in HIV-1 positive patients with deficient immunological response: an Italian randomized clinical trial.
Rusconi S, Vitiello P, Adorni F, Colella E, Focà E, Capetti A, Meraviglia P, Abeli C, Bonora S, D'Annunzio M, Di Biagio A, Di Pietro M, Butini L, Orofino G, Colafigli M, d'Ettorre G, Francisci D, Parruti G, Soria A, Buonomini AR, Tommasi C, Mosti S, Bai F, Di Nardo Stuppino S, Morosi M, Montano M, Tau P, Merlini E, Marchetti G. Rusconi S, et al. Among authors: vitiello p. PLoS One. 2013 Nov 14;8(11):e80157. doi: 10.1371/journal.pone.0080157. eCollection 2013. PLoS One. 2013. PMID: 24244635 Free PMC article. Clinical Trial.
96-week results of a dual therapy with darunavir/ritonavir plus rilpivirine once a day vs triple therapy in patients with suppressed viraemia: virological success and non-HIV related morbidity evaluation.
Di Cristo V, Adorni F, Maserati R, Annovazzi Lodi M, Bruno G, Maggi P, Volpe A, Vitiello P, Abeli C, Bonora S, Ferrara M, Cossu MV, Oreni ML, Colella E, Rusconi S. Di Cristo V, et al. Among authors: vitiello p. HIV Res Clin Pract. 2020 Feb;21(1):34-43. doi: 10.1080/25787489.2020.1734752. Epub 2020 Mar 4. HIV Res Clin Pract. 2020. PMID: 32129161 Clinical Trial.
Development and validation of a risk score for chronic kidney disease in HIV infection using prospective cohort data from the D:A:D study.
Mocroft A, Lundgren JD, Ross M, Law M, Reiss P, Kirk O, Smith C, Wentworth D, Neuhaus J, Fux CA, Moranne O, Morlat P, Johnson MA, Ryom L; D:A:D study group; Royal Free Hospital Clinic Cohort; INSIGHT study group; SMART study group; ESPRIT study group. Mocroft A, et al. PLoS Med. 2015 Mar 31;12(3):e1001809. doi: 10.1371/journal.pmed.1001809. eCollection 2015 Mar. PLoS Med. 2015. PMID: 25826420 Free PMC article.
Interleukin-2 therapy in patients with HIV infection.
INSIGHT-ESPRIT Study Group; SILCAAT Scientific Committee; Abrams D, Lévy Y, Losso MH, Babiker A, Collins G, Cooper DA, Darbyshire J, Emery S, Fox L, Gordin F, Lane HC, Lundgren JD, Mitsuyasu R, Neaton JD, Phillips A, Routy JP, Tambussi G, Wentworth D. INSIGHT-ESPRIT Study Group, et al. N Engl J Med. 2009 Oct 15;361(16):1548-59. doi: 10.1056/NEJMoa0903175. N Engl J Med. 2009. PMID: 19828532 Free PMC article. Clinical Trial.
118 results